Navigation Links
Transave, Inc. Secures $12.5 Million in New Financing
Date:10/2/2008

thcare.

"This financing, in addition to a $35M Series D financing closed in March, will enable us to complete our Arikace Phase II program for the treatment of Pseudomonas infections in cystic fibrosis patients," said Tim Whitten, Transave's chief executive officer. "It also allows us to broaden the Arikace clinical trial program by initiating a Phase II clinical trial in a second area of high unmet need: bronchiectasis patients who have pseudomonas lung infections."

Based on the strength of the Arikace clinical profile to date, the company has initiated a Phase II trial to evaluate the compound for treating Pseudomonas infections in patients with non-cystic fibrosis-related bronchiectasis in Europe and India. The U.S. Food and Drug Administration (FDA) has also agreed to the company's plans to expand this trial into the United States. Bronchiectasis is the permanent widening of the bronchi (the large tubes which begin at the bottom of the trachea and branch into the lungs). Individuals with bronchiectasis are vulnerable to recurrent respiratory infections, which often have a Pseudomonas component.

Kristen Kosofsky, managing director of Horizon, noted, "Our goal at Horizon is to support the growth and success of innovative companies like Transave that develop important next-generation technologies that serve as the cornerstone for improving human health and quality of life."

About Arikace (liposomal amikacin for inhalation)

Arikace is a form of the antibiotic amikacin that is enclosed in nanocapsules of lipid called liposomes. This proprietary next-generation liposomal technology prolongs release of amikacin in the lung while minimizing systemic exposure. The treatment uses biocompatible lipids endogenous to the lung that are formulated into small (0.3 micrometers), neutrally-charged liposomes that enable biofilm penetration and are highly efficient, with very low lipid-to-drug ratio (0.65). Arikace can be effectively delivered thr
'/>"/>

SOURCE Transave, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing
2. Northwest Secures US$1.0 Million Debt Financing
3. Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
4. Althea Technologies Secures $12 M Credit Line to Continue Facility Growth and Expansion
5. Progenitor Cell Therapy Secures Industry Accreditation
6. BIOCOM Institute Secures Non-Profit Designation and Funding
7. Cara Therapeutics Secures $12.3 Million in Series C Extension Financing
8. OMTEC 2008 Boasts Record Attendance and Secures Premier Position as Must-attend for Orthopaedic Companies
9. Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs
10. Novasys Medical Secures $49.5 Million in Series D Financing to Expand Commercialization of Its Renessa(R) Treatment for Incontinence in Women
11. Veran Medical Technologies Secures $4.75M in First Institutional Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... April 16, 2015  In recognition of World Hemophilia Day, ... advocacy groups to illuminate more than 15 prominent landmarks red ... Boston,s Zakim Bridge and Prudential Tower, ... Mercedes-Benz Superdome and Denver,s ... evening of April 17, and coincide with hemophilia community events ...
(Date:4/16/2015)... /CNW/ - Bioenterprise Corporation is pleased to announce that it ... Charlottetown , PEI.  Bioenterprise has established a 3-year ... for the commercialization of agricultural technologies and innovations. ... ADAPT.  They have been at the heart of agri-innovation ... Dave Smardon , President & CEO of Bioenterprise ...
(Date:4/16/2015)... 16, 2015  AnaptysBio, Inc., a leader in ... today announced the advancement of its first-in-class ... studies. The Company,s anti-IL-36R therapeutic antibody, called ... pustular psoriasis (GPP), an orphan systemic inflammatory ... wholly owned within AnaptysBio,s proprietary antibody pipeline ...
(Date:4/16/2015)... , April 16, 2015  EMD Serono today ... Darmstadt, Germany , appointed ... Head of Global Clinical Development.  Dr. Reicin brings ... experience in Oncology and Immunology. She is an ... served as a Vice President in various capacities ...
Breaking Biology Technology:Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4Bioenterprise Corporation Expands into the Maritimes 2AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3
... Accurate Measurement of Women,s Ovarian ... ... will be the first IVF center in the southeast to offer,the Repromedix ... woman,s egg supply by combining multiple factors,including the measurement of ovary-related hormones ...
... suit claims company insiders knowingly misrepresented the ... ... Hagens Berman Sobol Shapiro filed a,proposed class-action lawsuit on behalf ... executives,knowingly misrepresented the company and chief executive officer Gary A.,Reys, ...
... Eli Lilly and Company,strongly objects to implications in a ... suppressed results of negative clinical,trials., The story, based ... of,Medicine (NEJM), cited Prozac and Lilly as high-profile examples ... Not only was,the Times, story inaccurate when it comes ...
Cached Biology Technology:Georgia Reproductive Specialists is First in Southeast to Offer Pioneering Test of Women's Biological Clock 2Georgia Reproductive Specialists is First in Southeast to Offer Pioneering Test of Women's Biological Clock 3Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation 2Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation 3In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 2In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 3In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 4
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
(Date:4/6/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND SYSTEM FOR ... introduces a new revolutionary method and system to ... of miniature antenna modules for multiple purposes including ...
(Date:4/2/2015)... -- According to preliminary estimates Fingerprint Cards, ... than 125 MSEK. This exceeds the guidance provided by ... for Q1 2015 would be in line with the ... The operating result for the first quarter is estimated ... will as previously communicated be published on May 21. ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2
... (January 9, 2013) -- A new study by NYU School ... gut bacterium Helicobacter pylori ( H. pylori ) isn,t ... and may even protect against stroke and some cancers. The findings, ... period of some 12 years, are published online, January 9, in ...
... its Education Committee travel award to attend the Biophysical ... in Philadelphia, February 2-26, 2013. The recipients of this ... fellows, are selected based on scientific merit. Each ... will receives a travel grant, and will be ...
... of overweight and obese Americans has increased, the amount ... decreased -- especially for patients with high blood pressure ... Medicine researchers. More than 145 million adult Americans ... the National Ambulatory Medical Care Survey for the years ...
Cached Biology News:Disappearing bacterium may protect against stroke 2Disappearing bacterium may protect against stroke 3Biophysical Society announces winners of 2013 Education Committee travel awards 2Biophysical Society announces winners of 2013 Education Committee travel awards 3Biophysical Society announces winners of 2013 Education Committee travel awards 4Biophysical Society announces winners of 2013 Education Committee travel awards 5Biophysical Society announces winners of 2013 Education Committee travel awards 6Weight counseling decreases despite rise in obesity 2Weight counseling decreases despite rise in obesity 3
Sterile detoxified 10% bovine serum albumin (BSA) in Iscoves MDM. This BSA has been selected to support the optimal colony growth of human hematopoietic progenitor cells in methylcellulose-based medi...
... it uses a deep-UV deuterium bulb, which provides ... a shutter (controlled via a TTL signal or ... DH-2000 Deuterium Tungsten Halogen Light Source combines the ... sources in a single optical path. The combined-spectrum ...
... handy dispensers save space and organize ... other garb. They are the perfect ... used in labs, processing and manufacturing. ... and the particles they attract. Open-slot ...
... latest generation of the popular precision ... the iontophoresis of neural transport tracers ... tritiated amino acids into neural tissue, ... may also be used to make ...
Biology Products: